Eli Lilly said it would invest $3 billion to expand a recently acquired manufacturing facility to meet growing demand for its diabetes and weight-loss medicines. The drugmaker said the Kenosha County, ...
Dan Skovronsky, Eli Lilly Chief Scientific Officer, joins 'Fast Money' to talk Zepbound's recent trial results and what it ...
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products ...
Eli Lilly and Company has announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial.
(Reuters) - Eli Lilly said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant ...
Data suggests that dramatic weight loss, including via GLP-1 drugs, could save Americans big bucks in healthcare spending.
Lilly’s blockbuster weight-loss and diabetes drugs have made it the most valuable pharmaceutical company in the world.
People who consumed at least five ounces of any type of chocolate each week had a 10% lower risk of Type 2 diabetes, ...
These days, with its revenue booming and a market cap swelling to twice the size of | Eli Lilly said it will spend $3 billion ...
Under pressure to keep up with soaring demand for drug treatments for obesity, diabetes and other diseases, Eli Lilly and Co.
The initial rollout of Eli Lilly's weight loss drug Zepbound in the UK will first go to those with the great clinical need ...
Wall Street is chewing over data on Amgen’s weight loss injection, MariTde. Meanwhile, GE HealthCare will acquire a Japanese ...